Human Mesenchymal Stem Cells for Spinal Cord Injury

Author(s): Masoumeh Alishahi, Amir Anbiyaiee, Maryam Farzaneh*, Seyed E. Khoshnam*.

Journal Name: Current Stem Cell Research & Therapy

Volume 15 , Issue 4 , 2020

Become EABM
Become Reviewer


Spinal Cord Injury (SCI), as a devastating and life-altering neurological disorder, is one of the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and surgical decompression. Both the approaches have been observed to have adverse physiological effects on SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required for developing cell-based therapies. Multipotent stem cells, as a novel strategy for the treatment of tissue injury, may provide an effective therapeutic option against many neurological disorders. Mesenchymal stem cells (MSCs) or multipotent stromal cells can typically self-renew and generate various cell types. These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs), umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have remarkable potential for the development of regenerative therapies in animal models and humans with SCI. Herein, we summarize the therapeutic potential of human MSCs in the treatment of SCI.

Keywords: Spinal cord injury, cell-based therapies, stem cells, mesenchymal stem cells, devastating disease, somatic stem cells.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [340 - 348]
Pages: 9
DOI: 10.2174/1574888X15666200316164051
Price: $95

Article Metrics

PDF: 3